Limited protective effect of the CCR5Δ32/CCR5Δ32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus

被引:11
|
作者
Iversen, AKN
Christiansen, CB
Attermann, J
Eugen-Olsen, J
Schulman, S
Berntorp, E
Ingerslev, J
Fugger, L
Scheibel, E
Tengborn, L
Gerstoft, J
Dickmeiss, E
Svejgaard, A
Skinhoj, P
机构
[1] Aarhus Univ, Sch Med, Dept Med Microbiol & Immunol, Aarhus, Denmark
[2] Aarhus Univ, Dept Biostat, Aarhus, Denmark
[3] Skejby Hosp, Dept Clin Immunol, Aarhus, Denmark
[4] Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[5] Rigshosp, Dept Pediat Dis, Hemophilia Ctr, DK-2100 Copenhagen, Denmark
[6] Rigshosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark
[7] Rigshosp, Blood Bank, DK-2100 Copenhagen, Denmark
[8] Statens Serum Inst, Dept Virol, DK-2300 Copenhagen, Denmark
[9] Hvidovre Univ Hosp, Dept Infect Dis, Copenhagen, Denmark
[10] Karolinska Hosp, Dept Coagulat Disorders, S-10401 Stockholm, Sweden
[11] Malmo Univ Hosp, Dept Coagulat Disorders, Malmo, Sweden
[12] Sahlgrenska Hosp, Dept Coagulat Disorders, Gothenburg, Sweden
来源
JOURNAL OF INFECTIOUS DISEASES | 2003年 / 187卷 / 02期
关键词
D O I
10.1086/345881
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The relationship among CCR5 genotype, cytomegalovirus infection, and disease progression and death was studied among 159 human immunodeficiency virus (HIV)-infected patients with hemophilia. One patient (0.6%) had the CCR5Delta32/CCR5Delta32 genotype (which occurs in similar to2% of the Scandinavian population) and a rapid disease course. His HIV V3 region contained genotypic features attributable to X4 virus and resembled functionally verified X4 virus and virus from patients treated with a CD4 cell-stimulating drug, tucaresol. Age-related differences in disease progression rate and survival time were seen for CCR5/CCR5 patients. Surprisingly, no protective effect of the CCR5/CCR5Delta32 genotype on disease progression or survival was seen for children but was evident for adults. Age group-related immunologic differences might explain this variation, and transmission route and/or viral phenotype variation within donor virus may be related to the limited protection of the CCR5Delta32/ CCR5Delta32 genotype. Sequence comparisons indicate that X4 virus can be selected in vivo due to either absence of CCR5 receptors or relative increase of CXCR4 receptors.
引用
收藏
页码:215 / 225
页数:11
相关论文
共 50 条
  • [41] The CCR5Δ32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment
    Barroga, CF
    Raskino, C
    Fangon, MC
    Palumbo, PE
    Baker, CJ
    Englund, JA
    Spector, SA
    JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (02): : 413 - 419
  • [42] Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32
    Michael, NL
    Nelson, JAE
    Kewalramani, VN
    Chang, G
    O'Brien, SJ
    Mascola, JR
    Volsky, B
    Louder, M
    White, GC
    Litman, DR
    Swanstrom, R
    O'Brien, TR
    JOURNAL OF VIROLOGY, 1998, 72 (07) : 6040 - 6047
  • [43] CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status
    Hoffman, TL
    MacGregor, RR
    Burger, H
    Mick, R
    Doms, RW
    Collman, RG
    JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04): : 1093 - 1096
  • [44] Chemokine receptor CCR5 genotype influences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice
    Picchio, GR
    Gulizia, RJ
    Mosier, DE
    JOURNAL OF VIROLOGY, 1997, 71 (09) : 7124 - 7127
  • [45] Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection
    Veazey, RS
    Klasse, PJ
    Ketas, TJ
    Reeves, JD
    Piatak, M
    Kunstman, K
    Kuhmann, SE
    Marx, PA
    Lifson, JD
    Dufour, J
    Mefford, M
    Pandrea, I
    Wolinsky, SM
    Doms, RW
    DeMartino, JA
    Siciliano, SJ
    Lyons, K
    Springer, MS
    Moore, JP
    JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (10): : 1551 - 1562
  • [46] Use of G-Protein-Coupled and -Uncoupled CCR5 Receptors by CCR5 Inhibitor-Resistant and -Sensitive Human Immunodeficiency Virus Type 1 Variants
    Berro, Reem
    Yasmeen, Anila
    Abrol, Ravinder
    Trzaskowski, Bartosz
    Abi-Habib, Sarya
    Grunbeck, Amy
    Lascano, Danny
    Goddard, William A., III
    Klasse, Per Johan
    Sakmar, Thomas P.
    Moore, John P.
    JOURNAL OF VIROLOGY, 2013, 87 (12) : 6569 - 6581
  • [47] Activation of β-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis
    Mayanja-Kizza, H
    Wajja, A
    Wu, MD
    Peters, P
    Nalugwa, G
    Mubiru, F
    Aung, H
    Vanham, G
    Hirsch, C
    Whalen, C
    Ellner, J
    Toossi, Z
    JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (12): : 1801 - 1804
  • [48] Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1
    Hunt, Joshua S.
    Romanelli, Frank
    PHARMACOTHERAPY, 2009, 29 (03): : 295 - 304
  • [49] The CCR5 and CXCR4 coreceptors - Central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection
    Moore, JP
    Kitchen, SG
    Pugach, P
    Zack, JA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (01) : 111 - 126
  • [50] Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1
    Kuhmann, SE
    Platt, EJ
    Kozak, SL
    Kabat, D
    JOURNAL OF VIROLOGY, 2000, 74 (15) : 7005 - 7015